Drug Profile
ISA 102
Alternative Names: Cancer vaccine p53 - ISA Pharmaceutical; ISA-102; P53 Synthetic Long Peptides Vaccine; P53-SLP vaccineLatest Information Update: 17 Jan 2024
Price :
$50
*
At a glance
- Originator ISA Pharmaceuticals
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
- Discontinued Colorectal cancer; Ovarian cancer
Most Recent Events
- 17 Jan 2024 Preclinical trials in Cancer in Netherlands (unspecified route) (ISA Pharmaceuticals pipeline; January 2024)
- 21 Jun 2022 Phase-II clinical trials in Cancer in Netherlands (unspecified route) before June 2022 (ISA Pharmaceuticals pipeline, June 2022)
- 04 May 2021 Preclinical trials in Unspecified in Netherlands (unspecified route)